Literature DB >> 29275939

Costs of Care of Agitation Associated With Dementia in 8 European Countries: Results From the RightTimePlaceCare Study.

Nadège Costa1, Ansgar Wübker2, Adelaïde De Mauléon3, Sandra M G Zwakhalen4, David Challis5, Helena Leino-Kilpi6, Ingalill R Hallberg7, Astrid Stephan8, Adelaida Zabalegui9, Kai Saks10, Laurent Molinier11, Anders Wimo12, Bruno Vellas3, Dirk Sauerland13, Ingrid Binot3, Maria E Soto3.   

Abstract

OBJECTIVE: To estimate the additional societal costs for people living with dementia (PwD) with agitation in home care (HC) and institutional long-term care (ILTC) settings in 8 European countries.
DESIGN: Cross-sectional data from the RightTimePlaceCare cohort.
SETTING: HC and ILTC settings from 8 European countries (Estonia, Finland, France, Germany, Netherlands, Spain, Sweden, and England). PARTICIPANTS: A total of 1997 PwD (1217 in HC group and 780 lived in an ILTC) and their caregivers. MAIN OUTCOME MEASURES: Medical care, community care, and informal care were recorded using the Resource Utilization in Dementia (RUD) questionnaire. Agitation was assessed based on the agitation symptoms cluster defined by the presence of agitation and/or irritability and/or disinhibition and/or aberrant motor behavior items of the Neuropsychiatric Inventory Questionnaire (NPI-Q).
RESULTS: Total monthly mean cost differences due to agitation were 445€ in the HC setting and 561€ in the ILTC setting (P = .01 and .02, respectively). Informal care costs were the main driver in the HC group (73% of total costs) and institutional care costs were the main driver in the ILTC group (53% of total costs). After adjustments, the log link generalized linear mixed model showed an association between agitation symptoms and an increase of informal care costs by 17% per month in HC setting (P < .05).
CONCLUSION: This study found that agitation symptoms have a substantial impact on informal care costs in the community care setting. Future research is needed to evaluate which strategies may be efficient by improving the cost-effectiveness ratio and reducing the burden associated with informal care in the management of agitation in PwD.
Copyright © 2017 AMDA – The Society for Post-Acute and Long-Term Care Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dementia; Europe; agitation; costs; informal care; long-term care

Mesh:

Year:  2018        PMID: 29275939     DOI: 10.1016/j.jamda.2017.10.013

Source DB:  PubMed          Journal:  J Am Med Dir Assoc        ISSN: 1525-8610            Impact factor:   4.669


  13 in total

1.  Symptom Clusters of Neuropsychiatric Symptoms in Mild Cognitive Impairment and Their Comparative Risks of Dementia: A Cohort Study of 8530 Older Persons.

Authors:  Tau Ming Liew
Journal:  J Am Med Dir Assoc       Date:  2019-03-26       Impact factor: 4.669

2.  Identifying Better Outcome Measures to Improve Treatment of Agitation in Dementia: A Report from the EU/US/CTAD Task Force.

Authors:  M Sano; M Soto; M Carrillo; J Cummings; S Hendrix; J Mintzer; A Porsteinsson; P Rosenberg; L Schneider; J Touchon; P Aisen; B Vellas; C Lyketsos
Journal:  J Prev Alzheimers Dis       Date:  2018

3.  Effectiveness of Powerful Tools for Caregivers on Caregiver Burden and on Care Recipient Behavioral and Psychological Symptoms of Dementia: A Randomized Controlled Trial.

Authors:  Antonio Terracciano; Ashley Artese; Jenie Yeh; LaVon Edgerton; Lisa Granville; Damaris Aschwanden; Martina Luchetti; Robert L Glueckauf; Yannick Stephan; Angelina R Sutin; Paul Katz
Journal:  J Am Med Dir Assoc       Date:  2019-12-19       Impact factor: 4.669

4.  Healthcare resource utilisation and costs of agitation in people with dementia living in care homes in England - The Managing Agitation and Raising QUality of LifE in Dementia (MARQUE) study.

Authors:  Monica Panca; Gill Livingston; Julie Barber; Claudia Cooper; Francesca La Frenais; Louise Marston; Sian Cousins; Rachael M Hunter
Journal:  PLoS One       Date:  2019-02-26       Impact factor: 3.240

5.  Neuropsychiatric symptoms in patients with dementia and the longitudinal costs of informal care in the Cache County population.

Authors:  Gail B Rattinger; Chelsea L Sanders; Elizabeth Vernon; Sarah Schwartz; Stephanie Behrens; Constantine G Lyketsos; JoAnn T Tschanz
Journal:  Alzheimers Dement (N Y)       Date:  2019-03-11

Review 6.  Behavioral and Psychiatric Symptoms of Dementia and Rate of Decline in Alzheimer's Disease.

Authors:  Reena T Gottesman; Yaakov Stern
Journal:  Front Pharmacol       Date:  2019-09-24       Impact factor: 5.810

7.  Information and Communication Technologies, a Promising Way to Support Pharmacotherapy for the Behavioral and Psychological Symptoms of Dementia.

Authors:  Antoine Piau; Pierre Rumeau; Fati Nourhashemi; Maria Soto Martin
Journal:  Front Pharmacol       Date:  2019-09-30       Impact factor: 5.810

8.  MEDREV (pharmacy-health psychology intervention in people living with dementia with behaviour that challenges): the feasibility of measuring clinical outcomes and costs of the intervention.

Authors:  Ian D Maidment; Garry Barton; Niyah Campbell; Rachel Shaw; Nichola Seare; Chris Fox; Steve Iliffe; Emma Randle; Andrea Hilton; Graeme Brown; Nigel Barnes; Jane Wilcock; Sarah Gillespie; Sarah Damery
Journal:  BMC Health Serv Res       Date:  2020-03-02       Impact factor: 2.655

9.  Quality of life of patients with dementia in acute hospitals in Germany: a non-randomised, case-control study comparing a regular ward with a special care ward with dementia care concept.

Authors:  Daniel Lüdecke; Georg Poppele; Jens Klein; Christopher Kofahl
Journal:  BMJ Open       Date:  2019-09-06       Impact factor: 2.692

10.  Emergency department and hospital admissions among people with dementia living at home or in nursing homes: results of the European RightTimePlaceCare project on their frequency, associated factors and costs.

Authors:  F Javier Afonso-Argilés; Gabriele Meyer; Astrid Stephan; Mercè Comas; Ansgar Wübker; Helena Leino-Kilpi; Connie Lethin; Kai Saks; Maria Soto-Martin; Caroline Sutcliffe; Hilde Verbeek; Adelaida Zabalegui; Anna Renom-Guiteras
Journal:  BMC Geriatr       Date:  2020-11-05       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.